| Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial AO Kaseb, E Hasanov, HST Cao, L Xiao, JN Vauthey, SS Lee, BG Yavuz, ... The Lancet Gastroenterology & Hepatology 7 (3), 208-218, 2022 | 151 | 2022 |
| MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma E Hasanov, E Jonasch Expert opinion on investigational drugs 30 (5), 495-504, 2021 | 44 | 2021 |
| Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL E Hasanov, G Chen, P Chowdhury, J Weldon, Z Ding, E Jonasch, S Sen, ... Oncogene 36 (24), 3450-3463, 2017 | 44 | 2017 |
| Phase II study of two weeks on, one week off sunitinib scheduling in patients with metastatic renal cell carcinoma E Jonasch, RS Slack, DM Geynisman, E Hasanov, MI Milowsky, ... Journal of Clinical Oncology 36 (16), 1588-1593, 2018 | 43 | 2018 |
| A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma E Jonasch, E Hasanov, PG Corn, T Moss, KR Shaw, S Stovall, V Marcott, ... Annals of Oncology 28 (4), 804-808, 2017 | 40 | 2017 |
| The immunotherapy revolution in kidney cancer treatment: scientific rationale and first-generation results E Hasanov, J Gao, NM Tannir The Cancer Journal 26 (5), 419-431, 2020 | 28 | 2020 |
| Pilot study of dovitinib in patients with von Hippel-Lindau disease P Pilié, E Hasanov, SF Matin, AHH Woodson, VD Marcott, S Bird, ... Oncotarget 9 (34), 23390, 2018 | 26 | 2018 |
| Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma B Gok Yavuz, E Hasanov, SS Lee, YI Mohamed, MA Curran, EJ Koay, ... Journal of Hepatocellular Carcinoma, 1195-1207, 2021 | 24 | 2021 |
| An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma E Hasanov, DN Yeboa, MD Tucker, TA Swanson, TH Beckham, B Rini, ... CA: A Cancer Journal for Clinicians 72 (5), 454-489, 2022 | 19 | 2022 |
| Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas J Thouvenin, O Alhalabi, M Carlo, L Carril-Ajuria, L Hirsch, ... The Oncologist 27 (12), 1041-1047, 2022 | 18 | 2022 |
| Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab+ axitinib (A+ Ax) versus sunitinib (S). E Jonasch, E Hasanov, RJ Motzer, S Hariharan, TK Choueiri, B Huang, ... Journal of Clinical Oncology 38 (6_suppl), 687-687, 2020 | 13 | 2020 |
| Immune checkpoint therapy combinations in adult advanced MiT family translocation renal cell carcinomas O Alhalabi, J Thouvenin, S Négrier, YA Vano, L Campedel, E Hasanov, ... The Oncologist 28 (5), 433-439, 2023 | 10 | 2023 |
| Phase II study of carfilzomib in patients with refractory renal cell carcinoma E Hasanov, RSS Tidwell, P Fernandez, L Park, C McMichael, NM Tannir, ... Clinical Genitourinary Cancer 17 (6), 451-456, 2019 | 10 | 2019 |
| Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. E Hasanov, I Pimentel, M Cruellas, MA Lewis, E Jonasch, J Balmaña American Society of Clinical Oncology Educational book. American Society of …, 2022 | 8 | 2022 |
| Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC). J Thouvenin, O Alhalabi, L Hirsch, E Hasanov, P Barthelemy, DJ Martini, ... Journal of Clinical Oncology 39 (6_suppl), 274-274, 2021 | 8 | 2021 |
| T-cell large granular lymphocytic leukaemia in the context of rheumatoid arthritis E Hasanov, EV Fard, A Puravath, JS Johnston, S Peerbhai, ... The Lancet 392 (10152), 1071, 2018 | 8 | 2018 |
| Effects of tamoxifen on urinary incontinence: Case report and review of literature E Hasanov, M Hasanov, IM Kuria, R Hasanov, R Rzazade, E Jonasch, ... Medicine 96 (34), e6785, 2017 | 7 | 2017 |
| SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma XD Liu, YT Zhang, DJ McGrail, X Zhang, T Lam, A Hoang, E Hasanov, ... Clinical Cancer Research 29 (19), 4002-4015, 2023 | 6 | 2023 |
| Serum IGF-1 scores and clinical outcomes in the phase III imbrave150 study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma AO Kaseb, Y Guan, B Gok Yavuz, AR Abbas, S Lu, E Hasanov, HC Toh, ... Journal of Hepatocellular Carcinoma, 1065-1079, 2022 | 5 | 2022 |
| Outcomes of patients with intermediate‐risk or poor‐risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of … O Alhalabi, E Hasanov, NR Wilson, J Araujo, J Wang, MT Campbell, ... International journal of cancer 149 (2), 387-393, 2021 | 5 | 2021 |
Eric JonaschProfessor在 mdanderson.org 的电子邮件经过验证
